Polymeric Nanocarriers for Drug Delivery in Osteosarcoma Treatment.

Osteosarcoma (OS) is one of the most serious malignancies along with a high incidence in children and teenagers. Although the neoadjuvant chemotherapy of OS has made great progress and prolongs the five-year survival rates of patients to some extent, drugs are restrained from clinical application due to the unsatisfactory efficacy and severe side effects, especially for the systemic therapy through intravenous injection. The polymeric nanoparticles as anti-cancer drug nanocarriers make OS treatment more promising and effective. Specifically, various polymeric nanoparticles have been developed to overcome the difficulties in targeting delivery of drugs to OS tissue and/or cells through passive and/or active strategies. This review presents an overview on the development of polymeric nanoparticles for anti-cancer drug delivery in OS treatment, and briefly describes the challenge and opportunity for future development.

[1]  S. Toyokuni.  Novel aspects of oxidative stress-associated carcinogenesis. , 2006, Antioxidants & redox signaling.

[2]  D. Sen,et al.  Biological variations of lysozyme concentration in the tear fluids of healthy persons. , 1986, The British journal of ophthalmology.

[3]  H. Maeda,et al.  Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[4]  Chunsheng Xiao,et al.  Noncovalent interaction-assisted polymeric micelles for controlled drug delivery. , 2014, Chemical communications.

[5]  Chun Li,et al.  Challenges to effective cancer nanotheranostics. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[6]  P. Sriamornsak,et al.  Nucleotropic doxorubicin nanoparticles decrease cancer cell viability, destroy mitochondria, induce autophagy and enhance tumour necrosis , 2015, The Journal of pharmacy and pharmacology.

[7]  C. Figdor,et al.  Molecular analysis of the hematopoiesis supporting osteoblastic cell line U2-OS. , 2000, Experimental hematology.

[8]  C. Dass,et al.  Co‐nanoencapsulated doxorubicin and Dz13 control osteosarcoma progression in a murine model , 2013, The Journal of pharmacy and pharmacology.

[9]  G. Machak,et al.  Neoadjuvant chemotherapy and local radiotherapy for high-grade osteosarcoma of the extremities. , 2003, Mayo Clinic proceedings.

[10]  P. Couvreur,et al.  Nanocarriers’ entry into the cell: relevance to drug delivery , 2009, Cellular and Molecular Life Sciences.

[11]  Chunsheng Xiao,et al.  Polyion complex micelles with gradient pH-sensitivity for adjustable intracellular drug delivery , 2015 .

[12]  O. Rajabi,et al.  Efficacy of microwave hyperthermia and chemotherapy in the presence of gold nanoparticles: An in vitro study on osteosarcoma , 2011, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

[13]  Xiangyang Shi,et al.  Dendrimer-assisted formation of fluorescent nanogels for drug delivery and intracellular imaging. , 2014, Biomacromolecules.

[14]  E Lucarelli,et al.  Mesenchymal stem cells as delivery vehicle of porphyrin loaded nanoparticles: effective photoinduced in vitro killing of osteosarcoma. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[15]  D. Blakey,et al.  New coupling agents for the synthesis of immunotoxins containing a hindered disulfide bond with improved stability in vivo. , 1987, Cancer research.

[16]  Chaoliang He,et al.  Co-delivery of 10-hydroxycamptothecin with doxorubicin conjugated prodrugs for enhanced anticancer efficacy. , 2013, Macromolecular bioscience.

[17]  Xing-Jie Liang,et al.  pH-sensitive nano-systems for drug delivery in cancer therapy. , 2014, Biotechnology advances.

[18]  Chaoliang He,et al.  Facile preparation of a cationic poly(amino acid) vesicle for potential drug and gene co-delivery , 2011, Nanotechnology.

[19]  Chunsheng Xiao,et al.  Preclinical evaluation of antitumor activity of acid-sensitive PEGylated doxorubicin. , 2014, ACS applied materials & interfaces.

[20]  Hossein Hosseinkhani,et al.  Polymeric nanoparticles for therapy and imaging , 2014 .

[21]  Zhiyuan Zhong,et al.  cRGD-directed, NIR-responsive and robust AuNR/PEG-PCL hybrid nanoparticles for targeted chemotherapy of glioblastoma in vivo. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[22]  M. Uesaka,et al.  Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. , 2011, Nature nanotechnology.

[23]  Freya Q. Schafer,et al.  Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. , 2001, Free radical biology & medicine.

[24]  R. Jain,et al.  Photodynamic therapy for cancer , 2003, Nature Reviews Cancer.

[25]  You Han Bae,et al.  Drug targeting and tumor heterogeneity. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[26]  Jie Chen,et al.  pH-responsive drug delivery systems based on clickable poly(L-glutamic acid)-grafted comb copolymers , 2012, Macromolecular Research.

[27]  Arun K Iyer,et al.  Doxorubicin loaded Polymeric Nanoparticulate Delivery System to overcome drug resistance in osteosarcoma , 2009, BMC Cancer.

[28]  Stanley B. Brown,et al.  The present and future role of photodynamic therapy in cancer treatment. , 2004, The Lancet. Oncology.

[29]  S. Ferrari,et al.  Postrelapse survival in osteosarcoma of the extremities: prognostic factors for long-term survival. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  S. Aluri,et al.  Environmentally responsive peptides as anticancer drug carriers. , 2009, Advanced drug delivery reviews.

[31]  S. Loening,et al.  ALCAM/CD166 is up‐regulated in low‐grade prostate cancer and progressively lost in high‐grade lesions , 2003, The Prostate.

[32]  P. Choong,et al.  Osteosarcoma treatment: state of the art , 2009, Cancer and Metastasis Reviews.

[33]  Emanuel Fleige,et al.  Stimuli-responsive polymeric nanocarriers for the controlled transport of active compounds: concepts and applications. , 2012, Advanced drug delivery reviews.

[34]  R. N. Saha,et al.  Nanoparticulate drug delivery systems for cancer chemotherapy , 2010, Molecular membrane biology.

[35]  V. Muzykantov,et al.  Multifunctional Nanoparticles: Cost Versus Benefit of Adding Targeting and Imaging Capabilities , 2012, Science.

[36]  I. Lewis,et al.  Osteosarcoma treatment - where do we stand? A state of the art review. , 2014, Cancer treatment reviews.

[37]  Chaoliang He,et al.  One-step preparation of reduction-responsive poly(ethylene glycol)-poly (amino acid)s nanogels as efficient intracellular drug delivery platforms , 2011 .

[38]  You Han Bae,et al.  Recent progress in tumor pH targeting nanotechnology. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[39]  S. Burch,et al.  Photodynamic therapy of diseased bone. , 2006, Photodiagnosis and photodynamic therapy.

[40]  K. Greish,et al.  Anticancer nanomedicine and tumor vascular permeability; Where is the missing link? , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[41]  H. Maeda,et al.  A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. , 1986, Cancer research.

[42]  L. Costantino,et al.  Is there a clinical future for polymeric nanoparticles as brain-targeting drug delivery agents? , 2012, Drug discovery today.

[43]  Jeffery E. Raymond,et al.  Improving paclitaxel delivery: in vitro and in vivo characterization of PEGylated polyphosphoester-based nanocarriers. , 2015, Journal of the American Chemical Society.

[44]  Zhiyuan Zhong,et al.  Dual and multi-stimuli responsive polymeric nanoparticles for programmed site-specific drug delivery. , 2013, Biomaterials.

[45]  R. Gorlick,et al.  Chemotherapy resistance in osteosarcoma: current challenges and future directions , 2006, Expert review of anticancer therapy.

[46]  Véronique Préat,et al.  To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[47]  S R Piersma,et al.  Surface proteomic analysis of osteosarcoma identifies EPHA2 as receptor for targeted drug delivery , 2013, British Journal of Cancer.

[48]  Aniruddha Roy,et al.  Factors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[49]  João Rodrigues,et al.  Redox-responsive alginate nanogels with enhanced anticancer cytotoxicity. , 2013, Biomacromolecules.

[50]  O. Feron,et al.  Pyruvate into lactate and back: from the Warburg effect to symbiotic energy fuel exchange in cancer cells. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[51]  T. Ganz,et al.  Decreased clearance of Pseudomonas aeruginosa from airways of mice deficient in lysozyme M , 2005, Journal of leukocyte biology.

[52]  Chaoliang He,et al.  Core-cross-linked micellar nanoparticles from a linear-dendritic prodrug for dual-responsive drug delivery , 2014 .

[53]  F. Kiessling,et al.  Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[54]  Sanjiv S Gambhir,et al.  Cys-diabody quantum dot conjugates (immunoQdots) for cancer marker detection. , 2009, Bioconjugate chemistry.

[55]  Chaoliang He,et al.  Biocompatible reduction-responsive polypeptide micelles as nanocarriers for enhanced chemotherapy efficacy in vitro. , 2013, Journal of materials chemistry. B.

[56]  Joel A Swanson,et al.  Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities. , 2003, Advanced drug delivery reviews.

[57]  Stephanie E. A. Gratton,et al.  The effect of particle design on cellular internalization pathways , 2008, Proceedings of the National Academy of Sciences.

[58]  Chunsheng Xiao,et al.  Self-reinforced endocytoses of smart polypeptide nanogels for "on-demand" drug delivery. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[59]  Chunsheng Xiao,et al.  Versatile preparation of intracellular-acidity-sensitive oxime-linked polysaccharide-doxorubicin conjugate for malignancy therapeutic. , 2015, Biomaterials.

[60]  P. Carmeliet,et al.  Angiogenesis in cancer and other diseases , 2000, Nature.

[61]  Chengtie Wu,et al.  Nanotechnology in the targeted drug delivery for bone diseases and bone regeneration , 2013, International journal of nanomedicine.

[62]  Chunsheng Xiao,et al.  Emerging antitumor applications of extracellularly reengineered polymeric nanocarriers. , 2015, Biomaterials science.

[63]  Tao Chen,et al.  Self-assembled hybrid nanoparticles for targeted co-delivery of two drugs into cancer cells. , 2014, Chemical communications.

[64]  Mimi Y. Kim,et al.  Cell surface receptor expression patterns in osteosarcoma , 2012, Cancer.

[65]  R. Bellamkonda,et al.  A dual-ligand approach for enhancing targeting selectivity of therapeutic nanocarriers. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[66]  Chaoliang He,et al.  Preparation of photo-cross-linked pH-responsive polypeptide nanogels as potential carriers for controlled drug delivery , 2011 .

[67]  J. J. van den Oord,et al.  Activated leukocyte cell adhesion molecule/CD166, a marker of tumor progression in primary malignant melanoma of the skin. , 2000, The American journal of pathology.

[68]  Patrick Couvreur,et al.  Stimuli-responsive nanocarriers for drug delivery. , 2013, Nature materials.

[69]  R. Gorlick,et al.  New targets and approaches in osteosarcoma. , 2013, Pharmacology & therapeutics.

[70]  B. Wilson,et al.  Treatment of Canine Osseous Tumors with Photodynamic Therapy: A Pilot Study , 2009, Clinical orthopaedics and related research.

[71]  K. Janeway,et al.  Sequelae of osteosarcoma medical therapy: a review of rare acute toxicities and late effects. , 2010, The Lancet. Oncology.

[72]  Chaoliang He,et al.  Direct formation of cationic polypeptide vesicle as potential carrier for drug and gene , 2012 .

[73]  Neeraj Kumar,et al.  BSA-PLGA-Based Core-Shell Nanoparticles as Carrier System for Water-Soluble Drugs , 2013, Pharmaceutical Research.

[74]  Y. Meng.  Evaluation of Physicochemical Characteristics of Hydrophobically Modified Glycol Chitosan Nanoparticles and their Biocompatibility in Murine Osteosarcoma and Osteoblast-like Cells , 2014 .

[75]  J. Karp,et al.  Nanocarriers as an Emerging Platform for Cancer Therapy , 2022 .

[76]  K. Kataoka,et al.  Preclinical and clinical studies of anticancer agent‐incorporating polymer micelles , 2009, Cancer science.

[77]  Jin Sun,et al.  Folate and CD44 receptors dual-targeting hydrophobized hyaluronic acid paclitaxel-loaded polymeric micelles for overcoming multidrug resistance and improving tumor distribution. , 2014, Journal of pharmaceutical sciences.

[78]  A. Elaissari,et al.  Nanotechnology olymer-based nanocapsules for drug delivery , 2009 .

[79]  Kazunori Kataoka,et al.  Progress of drug-loaded polymeric micelles into clinical studies. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[80]  Xuesi Chen,et al.  Micellization of antineoplastic agent to significantly upregulate efficacy and security. , 2015, Macromolecular bioscience.

[81]  Xuesi Chen,et al.  Chirality-mediated polypeptide micelles for regulated drug delivery. , 2015, Acta biomaterialia.